Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study To Evaluate The Pharmacokinetics Of Ag-013736 In Subjects With Impaired Hepatic Function.

Trial Profile

A Phase 1 Study To Evaluate The Pharmacokinetics Of Ag-013736 In Subjects With Impaired Hepatic Function.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary)
  • Indications Colorectal cancer; Liver cancer; Renal cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Jan 2019 Results characterizing the physiological and molecular characteristics driving variability in axitinib AUCSS using physiologically based pharmacokinetic modeling using data from Pfizer trials (A4061019, A406010, A4061022, A4061036, A4061044, A4061055, A406105) published in the Journal of Clinical Pharmacology
    • 12 Mar 2016 Results assessing pharmacokinetics from this other trial presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 21 Nov 2008 Actual start date changed from June 2008 to May 2008, actual end date reported as October 2008 by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top